BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 10681382)

  • 1. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR; Lasker JM; Johnson EF; Raucy JL
    Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2002 May; 30(5):602-7. PubMed ID: 11950794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
    Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
    Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19.
    Yasumori T; Chen LS; Li QH; Ueda M; Tsuzuki T; Goldstein JA; Kato R; Yamazoe Y
    Biochem Pharmacol; 1999 Jun; 57(11):1297-303. PubMed ID: 10230773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.
    Palamanda J; Feng WW; Lin CC; Nomeir AA
    Drug Metab Dispos; 2000 Jan; 28(1):38-43. PubMed ID: 10611138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways.
    Bort R; Macé K; Boobis A; Gómez-Lechón MJ; Pfeifer A; Castell J
    Biochem Pharmacol; 1999 Sep; 58(5):787-96. PubMed ID: 10449188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes.
    Srivastava PK; Yun CH; Beaune PH; Ged C; Guengerich FP
    Mol Pharmacol; 1991 Jul; 40(1):69-79. PubMed ID: 1857342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.
    Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA
    Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.
    Goldstein JA; Faletto MB; Romkes-Sparks M; Sullivan T; Kitareewan S; Raucy JL; Lasker JM; Ghanayem BI
    Biochemistry; 1994 Feb; 33(7):1743-52. PubMed ID: 8110777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: comparison with mephenytoin and tolbutamide hydroxylations.
    Weaver RJ; Dickins M; Burke MD
    Biochem Pharmacol; 1995 Mar; 49(7):997-1004. PubMed ID: 7741772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.